KELOWNA, BC, July 25, 2013 /CNW/ - Today Invaron Pharmaceuticals
announced that its ongoing Phase IV study of INVOcell has resulted in
the first clinical pregnancy in Canada.
INVOcell is an innovative medical device that enables conception and
early embryo development to occur within a woman's own body rather than
in a laboratory. "The INVO procedure provides a needed alternative to
intrauterine inseminations and augments existing in vitro fertilization
(IVF) services," commented Jason Broome, President of Invaron
Pharmaceuticals. "Utilizing the vaginal cavity as an incubator has the
potential to dramatically increase access to fertility care because the
capital costs and ongoing operating expenses associated with a
traditional IVF laboratory are not part of the INVO procedure. This
allows considerable savings and can dramatically lower the overall cost
of IVF services while maintaining similar pregnancy rates".
The study is chaired by Dr. Robert Casper, Medical Director of Toronto
Centre for Advanced Reproductive Technology (TCART) in Toronto, ON. "We
are excited to have achieved the first clinical pregnancy in Canada
using INVOcell" said Dr. Casper. "We believe that the INVO procedure
may allow infertility treatment for couples who otherwise might not be
able to access IVF because of geographical or financial reasons.
INVOcell offers a new therapeutic option for patients and we are
excited to continue to explore the potential benefits in our phase IV
Dr. John McNaught, Medical Director of Fertility Ontario, who led
patient recruitment and cycle monitoring for the study, further
commented, "We are excited that several of the patients we enrolled in
the study have ongoing pregnancies. INVOcell is going to broaden the
choices available to fertility patients and we look forward to being a
part of that."
About Invaron Pharmaceuticals
Invaron is a Canadian company focusing exclusively on the acquisition of
niche drugs and medical devices. By facilitating local registration,
bridging clinical gaps, and launching innovative marketing strategies,
Invaron will meet the needs of Canadian patients in a variety of
INVOcellTM is a registered trademark of INVO Bioscience Inc., used under license
by Invaron Pharmaceuticals Inc.
SOURCE: Invaron Pharmaceuticals Inc.
For further information:
Invaron Pharmaceuticals Inc.
Dr. Robert Casper
Fertility Ontario contact
Dr. John McNaught